{"id":813071,"date":"2025-02-13T16:24:14","date_gmt":"2025-02-13T21:24:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/"},"modified":"2025-02-13T16:24:14","modified_gmt":"2025-02-13T21:24:14","slug":"exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/","title":{"rendered":"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit"},"content":{"rendered":"

<\/p>\n

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit<\/b><\/p>\n

— Presentation to be webcast on <\/i>www.exelixis.com<\/i><\/a> —<\/i><\/p>\n

ALAMEDA, Calif.–(BUSINESS WIRE<\/a>)–
\nExelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 Virtual Oncology Leadership Summit on Wednesday, February 19 at 2:00 p.m. ET \/ 11:00 a.m. PT.<\/p>\n

\nTo access the webcast link, log onto www.exelixis.com<\/a> and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days.<\/p>\n

About Exelixis<\/b><\/p>\n

\nExelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX\u00ae<\/sup> (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com<\/a>, follow @ExelixisInc<\/a> on X (Twitter), like Exelixis, Inc.<\/a> on Facebook and follow Exelixis<\/a> on LinkedIn.<\/p>\n

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250213810489\/en\/<\/a><\/span><\/p>\n

Varant Shirvanian
\n<\/i>
Director, Investor Relations
\n<\/i>
Exelixis, Inc.
\n<\/i>
650-837-7917
\n<\/i>
vshirvanian@exelixis.com<\/i><\/a><\/p>\n

Media Contact:
\n<\/b>
Hal Mackins
\n<\/i>
For Exelixis, Inc.
\n<\/i>
415-994-0040
\n<\/i>
hal@torchcommunications.com<\/i><\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Other Health Clinical Trials Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit — Presentation to be webcast on www.exelixis.com — ALAMEDA, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 Virtual Oncology Leadership Summit on Wednesday, February 19 at 2:00 p.m. ET \/ 11:00 a.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, … <\/p>\n

Continue reading “Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-813071","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nExelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit — Presentation to be webcast on www.exelixis.com — ALAMEDA, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 Virtual Oncology Leadership Summit on Wednesday, February 19 at 2:00 p.m. ET \/ 11:00 a.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, … Continue reading "Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-13T21:24:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250213810489r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit\",\"datePublished\":\"2025-02-13T21:24:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/\"},\"wordCount\":313,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250213810489r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/\",\"name\":\"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250213810489r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-02-13T21:24:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250213810489r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250213810489r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/","og_locale":"en_US","og_type":"article","og_title":"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - Market Newsdesk","og_description":"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit — Presentation to be webcast on www.exelixis.com — ALAMEDA, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 Virtual Oncology Leadership Summit on Wednesday, February 19 at 2:00 p.m. ET \/ 11:00 a.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, … Continue reading \"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-13T21:24:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250213810489r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit","datePublished":"2025-02-13T21:24:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/"},"wordCount":313,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250213810489r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/","name":"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250213810489r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-02-13T21:24:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250213810489r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250213810489r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exelixis-to-participate-in-the-citi-2025-virtual-oncology-leadership-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/813071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=813071"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/813071\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=813071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=813071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=813071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}